Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Merus N.V. (MRUS : NSDQ)

• Company Description    Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. Number of Employees: 221

• Price / Volume Information    Yesterday's Closing Price: $22.49 Daily Weekly Monthly 20 Day Moving Average: 378,167 shares Shares Outstanding: 46.53 (millions) Market Capitalization: $1,046.48 (millions) Beta: 0.75 52 Week High: $30.81 52 Week Low: $12.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.56% 15.04% 12 Week 16.35% 8.00% Year To Date 45.38% 32.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL UPPSALALAAN 17 - UTRECHT,P7 3584 NLD ph: 31-30-253-8800 fax: - s.spear@merus.nl http://www.merus.nl

• General Corporate Information    Officers Sven (Bill) Ante Lundberg - President; Chief Executive Officer Anand Mehra - Chairman Harry Shuman - Chief Accounting Officer Len Kanavy - Director Greg D. Perry - Director Peer Information Merus N.V. (CORR.) Merus N.V. (RSPI) Merus N.V. (CGXP) Merus N.V. (BGEN) Merus N.V. (GTBP) Merus N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N5749R100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/14/23 Share - Related Items Shares Outstanding: 46.53 Most Recent Split Date: (:1) Beta: 0.75 Market Capitalization: $1,046.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.52 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.81 Price/Cash Flow: - Price / Sales: 24.10 EPS Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: 52.49% Sales Growth vs. Year Ago Period: 15.82% vs. Previous Quarter: 26.56% ROE 03/31/23 - -55.80 12/31/22 - -44.86 09/30/22 - -20.48 ROA 03/31/23 - -38.62 12/31/22 - -31.73 09/30/22 - -14.64 Current Ratio 03/31/23 - 3.44 12/31/22 - 3.88 09/30/22 - 5.74 Quick Ratio 03/31/23 - 3.44 12/31/22 - 3.88 09/30/22 - 5.74 Operating Margin 03/31/23 - -350.08 12/31/22 - -315.48 09/30/22 - -139.04 Net Margin 03/31/23 - -350.08 12/31/22 - -315.48 09/30/22 - -139.04 Pre-Tax Margin 03/31/23 - -349.19 12/31/22 - -313.17 09/30/22 - -137.92 Book Value 03/31/23 - 4.67 12/31/22 - 5.34 09/30/22 - 6.51 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©